BRCA1 and neoplasm: In a recent study of 308 BRCA1/2mut tumours, interrogation of non-BRCA DNA Homologous Recombination Repair (HRR) genes showed no obvious effect on talazoparib efficacy of BRCA Loss of Heterozygosity (LOH), effect of HRR gene mutational burden and tumour homologous recombination deficiency, as assessed by genomic LOH (gLOH)] [27].